Literature DB >> 24140714

Calcium regulates FGF-23 expression in bone.

Valentin David1, Bing Dai, Aline Martin, Jinsong Huang, Xiaobin Han, L Darryl Quarles.   

Abstract

Calcium has recently been shown to regulate fibroblast growth factor 23 (FGF-23), a bone-derived phosphate and vitamin D-regulating hormone. To better understand the regulation of FGF-23 by calcium, phosphorus, 1,25 dihydroxyvitamin D3 [1,25(OH)2D], and PTH, we examined FGF-23 expression under basal conditions and in response to PTH, doxercalciferol, or high-calcium diet treatment in Gcm2(-/-) and Cyp27b1(-/-) mutant mice. Gcm2(-/-) mice exhibited low serum PTH and 1,25(OH)2D concentrations, hypocalcemia, and hyperphosphatemia, whereas Cyp27b1(-/-) mice had high PTH, undetectable 1,25(OH)2D, hypocalcemia, and hypophosphatemia. Serum FGF-23 levels were decreased in both mutant models. Doxercalciferol administration increased serum FGF-23 levels in both mutant models. PTH administration to Gcm2(-/-) mice also increased serum FGF-23 levels, in association with an increase in both 1,25(OH)2D and calcium concentrations. Multiple regression analysis of pooled data indicated that changes in FGF-23 were positively correlated with serum calcium and 1,25(OH)2D but not related to changes in serum phosphate concentrations. A high-calcium diet also increased serum FGF-23 concentrations in Cyp27b1(-/-) mice in the absence of 1,25(OH)2D and in Gcm2(-/-) mice with low PTH. The addition of calcium to the culture media also stimulated FGF-23 message expression in MC3T3-E1 osteoblasts. In addition, FGF-23 promoter activity in cultured osteoblasts was inhibited by the L-calcium-channel inhibitor nifedipine and stimulated by calcium ionophores. The effects of chronic low calcium to prevent 1,25(OH)2D and PTH stimulation of FGF-23 in these mutant mouse models suggest that suppression of FGF-23 plays an important physiological adaptive response to hypocalcemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24140714      PMCID: PMC3836077          DOI: 10.1210/en.2013-1627

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  73 in total

1.  Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

Authors:  Sharon M Moe; Miriam P Zidehsarai; Mary A Chambers; Lisa A Jackman; J Scott Radcliffe; Laurie L Trevino; Susan E Donahue; John R Asplin
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 8.237

2.  Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Authors:  Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

3.  Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background.

Authors:  Qisheng Tu; Min Pi; Gerard Karsenty; Leigh Simpson; Shiguang Liu; L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

4.  Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets.

Authors:  O Dardenne; J Prud'homme; A Arabian; F H Glorieux; R St-Arnaud
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

5.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

6.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

7.  Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.

Authors:  Hua Li; Aline Martin; Valentin David; L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-07       Impact factor: 4.310

8.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

9.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

Authors:  T Yamashita; M Yoshioka; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

10.  Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Kelsey Smith; Michael Epstein; Leigh K Keating; Harald Jüppner; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2010-07-14       Impact factor: 5.992

View more
  59 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Authors:  Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

Review 3.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

4.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

Review 5.  Defective skeletal mineralization in pediatric CKD.

Authors:  Katherine Wesseling-Perry
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 6.  The dynamic skeleton.

Authors:  Anda Gonciulea; Suzanne Jan de Beur
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

7.  Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial.

Authors:  T Kamelian; F Saki; M Jeddi; M H Dabbaghmanesh; G H R Omrani
Journal:  J Endocrinol Invest       Date:  2017-08-09       Impact factor: 4.256

8.  High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice.

Authors:  Hai-Tao Hou; Ya-Nan Wang; Shi-Ze Shao; Song Fu; Xiang-Peng Huang; Xiao-Hui Wang
Journal:  Exp Ther Med       Date:  2018-02-14       Impact factor: 2.447

Review 9.  Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions.

Authors:  L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

Review 10.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.